Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Looking for new pathways in colorectal cancer

ESMO 2016

7 - 11 Oct 2016

Published: 10 Oct 2016

Views: 2392

Rating:

Save

Prof Nils Brünner - Copenhagen University, Copenhagen, Denmark

Prof Brünner talks to ecancertv at ESMO 2016 about his institute's work looking at new pathways in colorectal cancer.

Biomarkers and screening are a focus, as well as combating drug resistance and drug repurposing.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Genomic testing: Awareness and effective communication between healthcare...

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

Somatic and germline heterogeneity across colorectal cancer patient...

Prof Jeffrey Weitzel - The University of Kansas Cancer Center, Kansas, USA

Somatic and germline heterogeneity across colorectal cancer patient characteristics: Implications for early cancer detection ( Prof Jeffrey Weitzel - The University of Kansas Cancer Center, Kansas, USA )

Latest treatments in oesophageal cancer

Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA

Latest treatments in oesophageal cancer ( Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA )

Navigating evidence-based care with limited resources in Africa

Dr Verna Vanderpuye - National center for Radiotherapy and Nuclear Medicine...

Navigating evidence-based care with limited resources in Africa ( Dr Verna Vanderpuye - National center for Radiotherapy and Nuclear Medicine, Accra, Ghana )

EGFR mutations in NSCLC - from biomarker to treatment selections in second line

Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo

EGFR mutations in NSCLC - from biomarker to treatment selections in second line ( Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo )

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )

An overview of treatment advances in gastric cancer

Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA

An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )

Optimum treatment strategy algorithm for mCRC

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Optimum treatment strategy algorithm for mCRC ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

More from ecancer